But there is nothing to stop Mr Lousada from calling himself a “therapist” in Britain today. Anybody can. The title ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target ...

Could a noninvasive, cutting-edge radiation therapy for cancer also be used to treat heart arrhythmias? Mayo Clinic researchers think so.

CERN's Fusillo magnet, with its unique rope-winding design, could revolutionize cancer treatment by making hadron therapy ...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to earnings of $1.73 per share a year ago. These ...

Floating in the Rio Negro river in the Brazilian Amazon, Luiz Felipe, who has Down Syndrome, beams as he hugs a pink dolphin ...

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by ...

Proton arc therapy offers a superior dose distribution compared with existing state-of-the-art proton delivery techniques ...